Cite
HARVARD Citation
Yamazaki, K. et al. (n.d.). P-253A phase I/II study of panitumumab combined with TAS-102 in patients (pts) with RAS wild-type (wt) metastatic colorectal cancer (mCRC) refractory to standard chemotherapy: APOLLON study. Annals of oncology. p. . [Online].